KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Alnylam Pharmaceuticals (ALNY) over the last 6 years, with Dec 2024 value amounting to $127.7 million.

  • Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) rose 6.81% to $137.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.3 million, marking a year-over-year increase of 6.81%. This contributed to the annual value of $127.7 million for FY2024, which is 2.20% up from last year.
  • According to the latest figures from FY2024, Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) is $127.7 million, which was up 2.20% from $124.9 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) registered a high of $127.7 million during FY2024, and its lowest value of $115.0 million during FY2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $124.7 million, with a median of $124.9 million in 2023.
  • Data for Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY increased of 5.24% (in 2020) over the last 5 years.
  • Over the past 5 years, Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $115.0 million in 2020, then increased by 3.01% to $118.5 million in 2021, then climbed by 2.73% to $121.7 million in 2022, then climbed by 2.64% to $124.9 million in 2023, then climbed by 2.20% to $127.7 million in 2024.